EyePoint Pharmaceuticals marked a -1.4% change today, compared to -0.0% for the S&P 500. Is it a good value at today's price of $9.63? Only an in-depth analysis can answer that question, but here are some facts that can give you an idea:
-
EyePoint Pharmaceuticals, Inc. focuses on developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders.
-
EyePoint Pharmaceuticals belongs to the Industrials sector, which has an average price to earnings (P/E) ratio of 20.49 and an average price to book (P/B) of 3.78
-
The company's P/B ratio is 5.77
-
EyePoint Pharmaceuticals has a trailing 12 month Price to Earnings (P/E) ratio of -3.2 based on its trailing 12 month price to earnings (EPS) of $-3.0 per share
-
Its forward P/E ratio is -4.9, based on its forward earnings per share (EPS) of $-1.95
-
Over the last four years, EyePoint Pharmaceuticals has averaged free cash flows of $-37588333.3, which on average grew -0.0%
-
EYPT's gross profit margins have averaged 54.7 % over the last four years and during this time they had a growth rate of -0.0 % and a coefficient of variability of 7.2 %.
-
EyePoint Pharmaceuticals has moved 4.0% over the last year compared to 12.0% for the S&P 500 -- a difference of -8.0%
-
EYPT has an average analyst rating of buy and is -69.67% away from its mean target price of $31.75 per share